Imap (Fluspirilene)

Fluspirilene works by blocking dopamine D2 receptors in the brain, reducing excessive dopaminergic activity that contributes to psychotic symptoms. This antagonism stabilizes neurotransmission, leading to a decrease in hallucinations, delusions, and other features of schizophrenia.

The dosage of Imap is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. The prescriber will select the appropriate dose, frequency, and duration in accordance with local guidelines and the product’s labeling.

Safety data for fluspirilene in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Clinicians should discuss individual risks with the patient and consider alternative therapies when appropriate.

To order Imap, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling), and any required import documentation.

Imap (fluspirilene) belongs to the typical antipsychotic class, primarily acting as a dopamine D2 antagonist. Compared with atypical agents, it may have a higher propensity for extrapyramidal side effects but can be effective for patients who respond better to high‑potency typical drugs. Choice of therapy depends on efficacy, side‑effect profile, and individual patient factors.

Imap should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure proper cold‑chain conditions throughout distribution.

Imap is supplied as an intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and the prescribing information’s instructions.

The most serious risks include neuroleptic malignant syndrome, tardive dyskinesia, severe hypotension, and cardiac arrhythmias such as QT prolongation. Patients should be monitored closely for signs of these conditions, and treatment should be discontinued immediately if they occur.

Imap is contraindicated in patients with known hypersensitivity to fluspirilene or any excipients, those with a history of neuroleptic malignant syndrome, and individuals with severe cardiovascular instability. Caution is also advised for patients with uncontrolled diabetes, severe hepatic or renal impairment, and those taking interacting medications.